KOPRAN Share price

HISTORY BACKGROUND & PRESENT ACTIVITIES OF THE COMPANYKopran Ltd. was incorporated on April 26 1958 as a private limitedCompany under the name Kopran Chemical Company Pvt. Ltd. promoted byRamanlal V Shah Sevantilal A Shah Chimanlal G Sheth and Jivanlal MShah. The Company's name was changed to Kopran Chemical Company Limitedon August 24 1984 and further changed to Kopran Limited on August 221990.The Parijat Group acquired the Company in 1980 and revived it. TheCompany has since been making profits and the accumulated losses werewiped off by 1980-81. In August 1984 the Company was converted into apublic limited company and the name of the company was changed toKopran Ltd..Originally Kopran Ltd. manufactured pharmaceutical formulationsprominent amongst which are VENT TINI LOKIT and CISAPID. Theproduction of bulk drugs intermediaries was introduced in 1983. TheCompany established additional facilities in 1993 for the manufactureof 7- ADCA Cefadroxil C.I.M.C. Pen-G Acylase Enzyme and expandedfacilities for manufacture of SSP's. A Public Issue aggregating to Rs.14.40 Crs funded the Project. There were minor delays in theimplementation.Since then Kopran Ltd. has built up its strengths in the production ofwide range of Semi Synthetic Penicillin (SSPs) such as AmpicillinTrihydrate Amoxycillin Trihydrate and Cloxacillin Sodium. In 1986Rifampicin was launched in technical co-operation with YuhanCorporation South Korea. To support the expanding product base theCompany integrated backwards into manufacture of 6-APA an intermediaterequired for production of SSPs.The Company subsequently de-merged its SSP & 6-APA Bulk Drugs divisioninto a separate company namely KDL Biotech Ltd. (KDL) formerly knownas Kopran Drugs Ltd.. This demerger is primarily to enable the Companyto focus on its formulation business and specialty bulk drugs businesswhile KDL would become a dedicated SSP bulk drugs manufacturer.The formulation division has since then expanded and was structuredinto various strategic business units to enable exploitation of thedomestic and the international formulations market with a larger rangeof formulations. KL's main focus is on cardiology respiratorygastro-enterology anti-infectives and pain management. As a part ofits growth strategy KL plans to develop new products in therapeuticgroups like diabetics central nervous system and life style products.The company can undertake the activities proposed by it in view of thepresent approvals and no further approvals from any GovernmentAuthorities /RBI are required by the company to undertake the proposedactivities.As of March 31 2001 the Company's product portfolio consists of:Cardiovasculars 58%Respiratory 16%Alimentary 15%Anti-Infective 9%Musculo-Skeletals 2%The specialty bulk drug unit situated at Mahad provides most of the rawmaterials required for formulations manufactured for the domestic andthe export market.The Company has received certification under World Health Organization- Good Manufacturing Practice. The certificate WHO.GMP-Cer/409-2001/886/11 is valid up to 30th June 2002.